Imunon, Inc.
CLSN
Peringkat dalam Saham
#34957
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Harga Saham
$1.96
Terakhir disinkronkan: 2022-09-20
Kapitalisasi Pasar
$4.46M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
122.70%
Negara
US
Perdagangan Imunon, Inc. (CLSN)
Kategori
Healthcare
Riwayat hasil dividen untuk Imunon, Inc. (CLSN)
Hasil dividen (TTM) dari Imunon, Inc. (simbol saham: CLSN) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Imunon, Inc. (CLSN) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
| Perusahaan | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
